06:35 EDT Summit Therapeutics (SMMT) jumps 13% to $29.79 after results from HARMONi trial
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics announces topline results from Phase 3 HARMONi trial
- Summit Therapeutics: Buy Rating Backed by Promising Ivonescimab Trial and Favorable PFS Outcomes
- Summit Therapeutics Positioned for Growth: Buy Rating Supported by Strategic Value and Acquisition Potential
- Summit Therapeutics initiated with a Buy at Clear Street
- Summit Therapeutics initiated with a Buy at TD Cowen